FDA To Use Enforcement Discretion Regarding Changes To NDAs, ANDAs
This article was originally published in The Pink Sheet Daily
Executive Summary
Post-approval manufacturing changes made to comply with U.S. Pharmacopeia standards may be submitted in an annual report, an FDA guidance states. The agency plans to clarify the types of changes that can be submitted in an annual report instead of a supplemental filing in an upcoming guidance.
You may also be interested in...
Manufacturing Changes To Comply With USP Standards Require Supplements In Certain Cases, FDA Says
FDA final manufacturing rule states that changes made to comply with USP standards that relax acceptance criteria or delete tests would require changes-being-effected supplement. Other USP compliance changes would only require annual reports.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles